Drugs / XL820
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00350831 | Jul 2006 → ? | cancer | Exelixis | Completed | No outcome recorded |
| Phase 1 | NCT00129571 | Aug 2005 → ? | cancer | Exelixis | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00570635 | Dec 2007 → May 2009 | gastrointestinal stromal tumor | Exelixis | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00350831 ↗ |
| Action | Inhibit | “KIT inhibitor” NCT00350831 ↗ |
| Route | Oral | “Administered Orally” NCT00129571 ↗ |
| Target | KIT | “KIT inhibitor” NCT00350831 ↗ |